Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Starlix Takes Aim At Diabetes Prevention With 8,000-Patient Study

Executive Summary

Novartis will seek a diabetes prevention claim for its type 2 diabetes therapy Starlix with data generated by an 8,000-patient outcomes study.

You may also be interested in...



Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years

Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.

Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years

Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.

Genentech Xolair Brand Awareness Reaches 55% Among Allergists

Brand awareness of Genentech's asthma drug Xolair (omalizumab) is over 50% among allergists as a result of Genentech's market preparation efforts, compared to 48% in the first quarter, Chief Operating Officer Myrtle Potter reported during an analyst meeting in New York City Feb. 21.

Related Content

UsernamePublicRestriction

Register

PS037403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel